President Donald Trump signed an executive order Thursday calling for 100% tariffs on name-brand pharmaceuticals that are produced overseas as the Trump administration looks to bolster drug manufacturing in the U.S.

The executive order comes after Trump made a similar move last year, in which the president warned he would place 100% tariffs on pharmacuetical products unless the company was building its plant in the United States. 

"Despite being the world leader in research and development for most innovative pharmaceuticals ... The United States is heavily reliant on imports, threatening to limit United States access to life-saving medications in the event of global supply chain disruption due to geopolitical or economic disruption," the order reads. 

The European Union, Japan, Liechtenstein, South Korea, Switzerland and the United Kingdom are exempt from the new duties because of existing trade deals with the U.S., which Trump claimed "further United States economic and national security interests." 

The president said he was authorizing the tariffs under the Trade Act of 1974 and section 232 of the Trade Expansion Act of 1962, which were not targeted in a recent Supreme Court order that invalidated Trump's orders under the International Emergency Economic Powers Act.

Misty Severi is a news reporter for Just The News. You can follow her on X for more coverage.